Analyse MDxHealth SA (MDXH) — Kairos Score 55/100

À propos de MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 1 achats et 0 ventes déclarés par les dirigeants de MDxHealth SA.

🏦 Hedge Funds

3 fonds institutionnels déclarent une position sur MDXH dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur MDXH.

• MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution
• MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.